Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125851051 | 12585105 | 1 | I | 20131201 | 20160718 | 20160723 | 20160723 | EXP | GB-MHRA-ADR 23559806 | GB-ACCORD-042645 | ACCORD | 72.00 | YR | F | Y | 66.67000 | KG | 20160723 | CN | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125851051 | 12585105 | 1 | PS | SIMVASTATIN. | SIMVASTATIN | 1 | Oral | PREVIOUSLY RECEIVED 20 MG FROM 01-AUG-2013 TO SEP-2013. | N | 78155 | 40 | MG | |||||||
| 125851051 | 12585105 | 2 | C | INDERAL LA | PROPRANOLOL HYDROCHLORIDE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125851051 | 12585105 | 1 | Type IIa hyperlipidaemia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125851051 | 12585105 | OT |
| 125851051 | 12585105 | HO |
| 125851051 | 12585105 | DS |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125851051 | 12585105 | Motor dysfunction | |
| 125851051 | 12585105 | Muscle spasms | |
| 125851051 | 12585105 | Myalgia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125851051 | 12585105 | 1 | 20140101 | 0 |